Neurology:患者知情同意方式对临床特征的影响!

2017-08-27 xing.T MedSci原创

由此可见,通过亲属获得知情同意的患者年龄较大、卒中病情更严重并且失语症患病率更高,相比于自己获得知情同意的患者。在整个国家患者知情同意的方式变化可能影响试验结果。

近日,神经病学领域权威取杂志Neurology上发表了一篇研究文章,研究人员旨在明确患者知情同意的方式,即患者自己知情同意或患者家属知情同意,是否会影响急性卒中患者的临床特征。

研究人员分析了WAKE-UP研究中1005名患者获得知情同意的方式,这是一项由研究者发起的、随机、安慰剂对照试验,该研究是在6个欧洲国家的发病时间不明的接受以核磁共振为基础溶栓治疗的卒中患者中完成的。研究人员将自己获得知情同意的患者与通过亲属获得知情同意的患者的基线临床指标进行比较。

在该研究中,有359例(35.7%)患者通过患者亲属获得知情同意。通过亲属获得知情同意的患者年龄较大(中位数为71岁vs. 66岁,p<0.0001)、动脉高血压发生率较高(58.2% vs. 43.4%,p<0.0001);并且,国立卫生研究院卒中量表得分较高(中位数为11 vs. 5,p<0.0001),失语症更常见(73.7% vs. 20%,p<0.0001)。不同国家通过亲属获得知情同意的患者比例有所不同(P<0.0001),从西班牙的77.1%到丹麦的1.2%。

由此可见,通过亲属获得知情同意的患者年龄较大、卒中病情更严重并且失语症患病率更高,相比于自己获得知情同意的患者。在整个国家患者知情同意的方式变化可能影响试验结果。

原始出处:

Götz Thomalla,et al. Effect of informed consent on patient characteristics in a stroke thrombolysis trial.Neurology. 2017. http://dx.doi.org/10.1212/WNL.0000000000004414

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1842866, encodeId=cf711842866cc, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Jul 01 09:34:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000084, encodeId=2674200008492, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 30 20:34:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512386, encodeId=ad571512386e7, content=<a href='/topic/show?id=6863e314797' target=_blank style='color:#2F92EE;'>#知情同意#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73147, encryptionId=6863e314797, topicName=知情同意)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a410466491, createdName=1249862am75(暂无昵称), createdTime=Tue Aug 29 09:34:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238003, encodeId=b8d123800303, content=很好的文章.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Aug 28 11:52:54 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237808, encodeId=01f823e80824, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Aug 27 23:30:51 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237750, encodeId=151023e7501f, content=学习啦!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Sun Aug 27 18:38:37 CST 2017, time=2017-08-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1842866, encodeId=cf711842866cc, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Jul 01 09:34:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000084, encodeId=2674200008492, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 30 20:34:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512386, encodeId=ad571512386e7, content=<a href='/topic/show?id=6863e314797' target=_blank style='color:#2F92EE;'>#知情同意#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73147, encryptionId=6863e314797, topicName=知情同意)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a410466491, createdName=1249862am75(暂无昵称), createdTime=Tue Aug 29 09:34:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238003, encodeId=b8d123800303, content=很好的文章.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Aug 28 11:52:54 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237808, encodeId=01f823e80824, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Aug 27 23:30:51 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237750, encodeId=151023e7501f, content=学习啦!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Sun Aug 27 18:38:37 CST 2017, time=2017-08-27, status=1, ipAttribution=)]
    2018-03-30 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1842866, encodeId=cf711842866cc, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Jul 01 09:34:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000084, encodeId=2674200008492, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 30 20:34:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512386, encodeId=ad571512386e7, content=<a href='/topic/show?id=6863e314797' target=_blank style='color:#2F92EE;'>#知情同意#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73147, encryptionId=6863e314797, topicName=知情同意)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a410466491, createdName=1249862am75(暂无昵称), createdTime=Tue Aug 29 09:34:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238003, encodeId=b8d123800303, content=很好的文章.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Aug 28 11:52:54 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237808, encodeId=01f823e80824, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Aug 27 23:30:51 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237750, encodeId=151023e7501f, content=学习啦!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Sun Aug 27 18:38:37 CST 2017, time=2017-08-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1842866, encodeId=cf711842866cc, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Jul 01 09:34:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000084, encodeId=2674200008492, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 30 20:34:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512386, encodeId=ad571512386e7, content=<a href='/topic/show?id=6863e314797' target=_blank style='color:#2F92EE;'>#知情同意#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73147, encryptionId=6863e314797, topicName=知情同意)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a410466491, createdName=1249862am75(暂无昵称), createdTime=Tue Aug 29 09:34:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238003, encodeId=b8d123800303, content=很好的文章.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Aug 28 11:52:54 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237808, encodeId=01f823e80824, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Aug 27 23:30:51 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237750, encodeId=151023e7501f, content=学习啦!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Sun Aug 27 18:38:37 CST 2017, time=2017-08-27, status=1, ipAttribution=)]
    2017-08-28 清风拂面

    很好的文章.谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1842866, encodeId=cf711842866cc, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Jul 01 09:34:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000084, encodeId=2674200008492, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 30 20:34:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512386, encodeId=ad571512386e7, content=<a href='/topic/show?id=6863e314797' target=_blank style='color:#2F92EE;'>#知情同意#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73147, encryptionId=6863e314797, topicName=知情同意)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a410466491, createdName=1249862am75(暂无昵称), createdTime=Tue Aug 29 09:34:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238003, encodeId=b8d123800303, content=很好的文章.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Aug 28 11:52:54 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237808, encodeId=01f823e80824, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Aug 27 23:30:51 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237750, encodeId=151023e7501f, content=学习啦!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Sun Aug 27 18:38:37 CST 2017, time=2017-08-27, status=1, ipAttribution=)]
    2017-08-27 184****9840

    学习了谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1842866, encodeId=cf711842866cc, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Jul 01 09:34:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000084, encodeId=2674200008492, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Mar 30 20:34:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512386, encodeId=ad571512386e7, content=<a href='/topic/show?id=6863e314797' target=_blank style='color:#2F92EE;'>#知情同意#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73147, encryptionId=6863e314797, topicName=知情同意)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a410466491, createdName=1249862am75(暂无昵称), createdTime=Tue Aug 29 09:34:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238003, encodeId=b8d123800303, content=很好的文章.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Aug 28 11:52:54 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237808, encodeId=01f823e80824, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Aug 27 23:30:51 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237750, encodeId=151023e7501f, content=学习啦!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Sun Aug 27 18:38:37 CST 2017, time=2017-08-27, status=1, ipAttribution=)]
    2017-08-27 tanxingdoctor

    学习啦!谢谢分享

    0

相关资讯

医疗大数据时代,知情同意怎么办?

5月下旬,马云、马化腾、雷军、周鸿祎等互联网巨头齐聚贵州,参加“2015年贵阳国际大数据产业博览会暨全球大数据时代贵阳峰会”,李克强总理发去贺信,马凯副总理到场发表演讲。会上,周鸿祎提出了“大数据的伦理和道德问题”。他指出了三点:1. 用户数据的所有权归用户;2. 用户在知情同意的基础上,用自己的数据换取企业或政府的服务;3. 存储数据的主题对数据安全负责。知情同意,在医疗领域不是一个新鲜的词。但

知情同意: 不仅仅是一个签名!

Informedconsent:Morethangettingasignature 编译自TheJointCommission.QuickSafetyIssue21February2016 图片来自网络 【问题】 有效的知情同意是患者能够完全理解并同意接受即将实施的治疗或手术,完成这个过程并非简单,需要多重挑战。即使患者已经签署知情同意书,他们也常常并不了解

情况紧急但家属拒不签字 医院该怎么办?

您还记得当年轰动一时的发生在北京某医院的一起与知情同意有关的案例吗?因为“准丈夫”拒绝在手术同意书上签字,致使“妻子”连同腹中的胎儿在医疗设施齐全的医院里双双送命。今天,我们将重温这一案例,理解医院与家属之间为何“沟而不通”。其中的哪些经验教训能更好地指导今后的工作?案例再现李丽云跟随比她大12岁的肖志军到北京打工,每个月温饱都很难维持,更不能想结婚生子的事情了。虽然他们不是正式夫妻,但感情很

护士被判2年,因救活“死婴”后送人……

医务人员在医疗行为中,一定要严守法律的底线,我们从来不排斥道德,但何为道德,自己心中要有一杆秤,不要被自己心中所谓的道德蒙蔽后触犯法律,只能自食其果。

J Natl Cancer I:改善低健康素养患者知情同意的语言策略

2017年5月,发表在《J Natl Cancer Inst》的一项由美国科学家进行的临床试验,旨在改善低健康素养患者知情同意的语言策略。背景:改善参加随机临床试验(RCT)患者的知情同意,是癌症沟通中一个核心挑战。本研究检测了旨在增强具有不同健康素养水平的患者随机理解的策略,并识别打算参与癌症RCT的认知和情感预测因素。方法:仅用测试后试验设计,癌症患者(500人)随机分配到3种中任一种解释随机

专家告诉你:临床研究中,如何获取知情同意?

结合BRIGHT研究谈知情同意的获取 临床研究中不可略过的细节ST段抬高心肌梗死(STEMI)患者入组临床试验是否要获得知情同意?HEAT-PPCI研究在患者入组后延迟获取知情同意的做法,自研究公布之初就伴随着关于伦理问题的争论。其支持方提到,STEMI患者病情的紧急、可能的意识障碍造成了知情同意获取的困难。然而,由我国沈阳军区总医院韩雅玲院士牵头、与HEAT-PPCI情况类似的BRIGHT研